Aclipse Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
411 Swedeland Rd Ste 23-1080, King of Pr...Website
www.aclipsetherapeutics.comRevenue
<$5 MillionIndustry
About Aclipse Therapeutics
Aclipse Therapeutics specializes in developing innovative therapeutics aimed at treating life-threatening and severe diseases, particularly focusing on neuromuscular conditions. The company utilizes genomic, proteomic, and biomarker data to create disease-modifying drug candidates, with M107 targeting gastroparesis and M102 aimed at amyotrophic lateral sclerosis (ALS). Their approach emphasizes understanding molecular pathways related to inflammation and cellular stress to enhance patient outcomes. Aclipse Therapeutics is transitioning into a clinical stage development company, committed to delivering breakthrough medicines for patients.Explore more
Aclipse Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Aclipse Therapeutics
Compare insights from companies similar to Aclipse Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aclipse Therapeutics Tech Stack
A closer look at the technologies used by Aclipse Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aclipse Therapeutics
Sign Up For FreeTo access detailed company insights
Aclipse Therapeutics specializes in developing innovative therapeutics aimed at treating life-threatening and severe diseases, particularly focusing on neuromuscular conditions. The company utilizes genomic, proteomic, and biomarker data to create disease-modifying drug candidates, with M107 targeting gastroparesis and M102 aimed at amyotrophic lat... Read More
